NovavaxNVAX
About: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Employees: 1,992
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
35% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 31
10% more capital invested
Capital invested by funds: $1.08B [Q2] → $1.19B (+$104M) [Q3]
4% more funds holding
Funds holding: 224 [Q2] → 232 (+8) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 64
2.12% less ownership
Funds ownership: 60.72% [Q2] → 58.6% (-2.12%) [Q3]
25% less call options, than puts
Call options by funds: $124M | Put options by funds: $164M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Vernon Bernardino 37% 1-year accuracy 22 / 59 met price target | 126%upside $19 | Buy Reiterated | 10 Dec 2024 |
Financial journalist opinion
Based on 7 articles about NVAX published over the past 30 days
